Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
No, clinical study data (PROMISE Study) did not indicate this.
You should avoid massage therapy near the inserted sensor site. Massage therapy near the sensor site could cause discomfort or skin irritation.
The simple answer is no. While you may optionally calibrate the Eversense E3 System more frequently, (daily calibrations entries must be spaced at least one hour apart), this will not impact the accuracy of the system.
No. The Eversense E3 Sensor is only compatible with the Eversense E3 Smart Transmitter. The Eversense E3 Smart Transmitter is only compatible with the Eversense E3 Sensor.
- Allowed via phone operating system
- Always plays at maximum phone volume, cannot be changed by user – this implementation is from the phone’s OS, not from Eversense
- Low Glucose Alert
- Out of Range Low Glucose Alert
- Use cases
- Loud working environment
- Heavy sleeper who may not feel vibes
- NOT intended for switching on during a meeting, for example
Glucose Targets are the low and high levels of the range you are aiming for throughout the day. These settings are used in the app to indicate when glucose values are in your target range.
Note: Target range values must be set within alert range values. Do not change your glucose alert levels without consulting with your health care professional.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060